In the renal clear cell carcinoma (KIRC) cohort treated with nivolumab anti-PD-1 monoclonal antibody, we found that patients with a low MRGPI have significantly better ICI therapy efficacy and higher OS rates than patients with a high MRGPI (Figure 5J). Here, PDCD1 is linked to clear cell renal carcinoma.